ENDRA director granted 60,324 RSUs

ENDRA Life Sciences Inc. director Anthony DiGiandomenico reported a stock-based award of the company’s common stock.

Rhea-AI Filing Summary

ENDRA Life Sciences Inc. director Anthony DiGiandomenico reported a stock-based award of the company’s common stock. On January 21, 2026, he acquired 60,324 shares at a price of $0, representing restricted stock units (RSUs) that convert to common stock on a one-for-one basis. These RSUs will vest in full on January 21, 2027, meaning he will receive the underlying shares on that date if vesting conditions are met. After this grant, he beneficially owns 136,589 shares of ENDRA common stock, held directly, which includes unvested RSUs.

Insider Trade Summary

Grant/Award: 60,324 shares

Grant/Award 1 txn

Insider DIGIANDOMENICO ANTHONY

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	60,324	$0.00	$0.00

Holdings After Transaction: Common Stock — 136,589 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.
2. F2. Includes unvested RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NDRA director Anthony DiGiandomenico report?

Director Anthony DiGiandomenico reported acquiring 60,324 shares of ENDRA Life Sciences Inc. common stock on January 21, 2026 through a stock-based award.

What type of shares did Anthony DiGiandomenico receive in this NDRA Form 4 filing?

He received restricted stock units (RSUs) that convert into ENDRA Life Sciences common stock on a one-for-one basis.

When do the reported RSUs for NDRA’s director vest?

The RSUs granted to Anthony DiGiandomenico will vest in full on January 21, 2027, at which point they convert into common shares.

Did the NDRA director pay anything for the 60,324 shares reported?

No cash was paid for this grant; the 60,324 shares were acquired at a reported price of $0 per share as part of an equity award.

How many NDRA shares does Anthony DiGiandomenico beneficially own after this transaction?

Following the reported grant, he beneficially owns 136,589 shares of ENDRA Life Sciences common stock, held directly, which includes unvested RSUs.

Is the NDRA Form 4 transaction reported as direct or indirect ownership?

The Form 4 shows the 136,589 shares as direct (D) ownership, with no separate entity or indirect ownership structure disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/23/2026 - 07:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DIGIANDOMENICO ANTHONY

(Last) (First) (Middle)

C/O ENDRA LIFE SCIENCES INC.

3600 GREEN COURT, SUITE 350

(Street)

ANN ARBOR MI 48105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENDRA Life Sciences Inc. [ NDRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		A		60,324(1)	A	$0	136,589(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.

2. Includes unvested RSUs.

	/s/ Anthony DiGiandomenico by Mark Busch, attorney-in-fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.